Compare MEGI & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MEGI | MGTX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 792.7M | 909.1M |
| IPO Year | 2021 | 2018 |
| Metric | MEGI | MGTX |
|---|---|---|
| Price | $15.33 | $9.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.57 |
| AVG Volume (30 Days) | 147.5K | ★ 646.7K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | N/A | $141.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $13.42 | $5.02 |
| 52 Week High | $15.89 | $11.85 |
| Indicator | MEGI | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.07 | 47.17 |
| Support Level | $14.19 | $7.11 |
| Resistance Level | $15.37 | $9.65 |
| Average True Range (ATR) | 0.21 | 0.43 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 80.72 | 26.56 |
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.